{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:18:47Z","timestamp":1761211127849,"version":"build-2065373602"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Limited clinical evidence exists regarding the safety profile of amiodarone therapy in patients with heart failure (HF) who already have underlying cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The present study aimed to investigate the safety profile of amiodarone in patients with cirrhosis and HF concomitantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective cohort study with the TriNetX database using ICD-10 codes. Patients aged &gt; 18 years with HF and cirrhosis receiving amiodarone for atrial fibrillation\/flutter or ventricular tachycardia\/fibrillation were compared with those not receiving amiodarone as a control group. Patients with end-stage renal disease were excluded. The primary outcome was a composite of all-cause mortality or all-cause hospitalization\/emergency room visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>No significant differences in the primary outcome were found between the amiodarone and non-amiodarone groups (OR: 1.125 [95% CI: 0.956, 1.324]; P=0.158). The time-to-event analysis also revealed no significant differences in the primary outcome between the two groups (HR 0.949 [95% CI 0.816, 1.103], P=0.499). There were no significant differences in all-cause hospitalization\/ emergency room visits (OR: 1.013 [95% CI: 0.880, 1.166]; P= 0.121), all-cause mortality (OR: 1.031 [95% CI: 0.901, 1.179]; P=0.656), and worsening hepatic function between two groups (OR: 0.943 [95% CI: 0.798, 1.115]; P=0.494).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>result:<\/jats:title>\n                    <jats:p>No significant differences in the primary outcome were found between the amiodarone and non-amiodarone groups(OR: 1.125 [95% CI: 0.956, 1.324]; P=0.158). The time-to-event analysis also revealed no significant differences in the primary outcome between two groups (HR 0.949 [95% CI 0.816, 1.103], P=0.499). There were no significant differences in all-cause hospitalization\/emergency room visits (OR: 1.013 [95% CI: 0.880, 1.166]; P= 0.121), all-cause mortality (OR: 1.031 [95% CI: 0.901, 1.179]; P=0.656) , and worsening hepatic function between two groups (OR: 0.943 [95% CI: 0.798, 1.115]; P=0.494).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The amiodarone therapy in patients with underlying cirrhosis and heart failure may be reasonable with close liver function monitoring if the benefits outweigh the risks of amiodarone therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115748863361411250419155302","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:05:28Z","timestamp":1747033528000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Assessment of Amiodarone Use in Patients with Cirrhosis and Heart Failure"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-8025","authenticated-orcid":true,"given":"Kazuhiko","family":"Kido","sequence":"first","affiliation":[{"name":"Clinical Associate Professor, Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Room 1126 Health Science Center North, Morgantown, WV 26506, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Al-Mamun","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Systems and Policy, West Virginia University School of Pharmacy, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863361411250419155302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/241877\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863361411250419155302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:13:46Z","timestamp":1761210826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/241877\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748863361411250419155302","relation":{},"ISSN":["1574-8863"],"issn-type":[{"type":"print","value":"1574-8863"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}